Table 3 Changes in msSBP from baseline to 8 weeks of treatment

From: A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension

 

FAS

PPS

 

Placebo (n = 31)

SPH3127 50 mg (n = 30)

SPH3127 100 mg (n = 30)

SPH3127 200 mg (n = 30)

Placebo (n = 31)

SPH3127 50 mg (n = 26)

SPH3127 100 mg (n = 24)

SPH3127 200 mg (n = 27)

Pre-dosing

   Mean (SD)

146.7 (7.0)

148.0 (7.2)

147.6 (9.4)

147.4 (5.4)

146.7 (7.0)

147.1 (7.0)

146.8 (8.8)

147.2 (5.4)

8 weeks

   Mean (SD)

139.1 (11.1)

136.2 (14.5)

133.9 (12.8)

136.3 (11.5)

139.1 (11.1)

134.9 (15.0)

130.7 (12.0)

135.0 (9.8)

msSBP changes

   Mean (SD)

−7.7 (9.7)

−11.8 (13.0)

−13.8 (11.2)

−11.1 (13.1)

−7.7 (9.7)

−12.2 (13.8)

−16.2 (10.8)

−12.3 (11.9)

  1. Bold indicates that the difference between pre- and post-administration intra-groups is of statistical significance
  2. msSBP mean sitting systolic blood pressure, SD standard deviation
Back to article page